Drug intelligence / Profile preview

ramucirumab + docetaxel + gemcitabine

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination involves **ramucirumab**, a monoclonal antibody that inhibits vascular endothelial growth factor receptor 2 (VEGFR2), **docetaxel**, a chemotherapy agent, and **gemcitabine**, another chemotherapy drug. Ramucirumab is used to block angiogenesis, while docetaxel and gemcitabine are used to interfere with cell division and DNA synthesis, respectively. This combination is not a standard approved regimen but is being explored in clinical trials.

Other names: ramucirumab plus gemcitabine plus docetaxel

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)Microtubule

Beyond the preview

Go deeper on ramucirumab + docetaxel + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ramucirumab + docetaxel + gemcitabine.

Explore the full profile